ling Lin

Dr. ling Lin


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2018 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
BWBei Wang
Bei Wang
QZQiuwang Zhang
Qiuwang Zhang
LLling Lin
ling Lin
LPLi-Li Pan
Li-Li Pan
CHCheng-Yu He
Cheng-Yu He
MKMichael J. Kutryk
Michael J. Kutryk
Achilles tendons are the most common sites of tendon xanthomas that are commonly caused by disturbance of lipid metabolism. Achilles tendon thickening is the early characteristic of Achilles tendon xanthomas. The relationship between Achilles tendon thickness (ATT) and LDL-C levels, and risk factors of ATT in patients with hypercholesterolemia, have thus far been poorly documented. A total of 205 individuals, aged 18-75 years, were enrolled from March 2014 to March 2015. According to the LDL-C levels and the “Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults”, all subjects were divided into 3 groups: normal group (LDL-C < 3.37 mmol/L, n = 51); borderline LDL-C group (3.37 mmol/L ≤ LDL-C ≤ 4.12 mmol/L, n = 50); and hypercholesterolemia group (LDL ≥ 4.14 mmol/L, n = 104). ATT was measured using a standardized digital radiography method and the results were compared among the 3 groups. The correlation between ATT and serum LDL-C levels was analyzed by Pearson’s correlation, and the risk factors of ATT were determined by the logistic regression model. ATT in borderline LDL-C group was 8.24 ± 1.73 mm, markedly higher than 6.05 ± 0.28 mm of normal group (P < 0.05). ATT in hypercholesterolemia group was 9.42 ± 3.63 mm which was significantly higher than that of normal group (P < 0.005) and that of borderline LDL-C group (P < 0.05). There was a positive correlation between the serum LDL-C levels and ATT (r = 0.346, P < 0.001). The serum LDL-C level was a risk factor (OR = 1.871, 95% CI: 1.067-3.280) while the levels of HDL-C (OR = 0.099, 95% CI: 0.017-0.573) and Apo AI (OR = 0.035, 95% CI: 0.003-0.412) were protective factors of ATT. ATT might serve as a valuable auxiliary diagnostic index for hypercholesterolemia and used for the assessment and management of cardiovascular disease.

31 August 2023 in eClinicalMedicine
Verified
Journal Article
Open access
BWBei Wang
Bei Wang
HLHai-Jun Li
Hai-Jun Li
MCMi-Mi Cai
Mi-Mi Cai
ZLZhao-Xin Lin
Zhao-Xin Lin
XOXia-Fei Ou
Xia-Fei Ou
LLling Lin
ling Lin
This study aimed to evaluate the efficacy and safety of RAY1216, a novel inhibitor of 3-chymotrypsin-like cysteine protease (3CLpro), in adults with coronavirus disease 2019 (COVID-19). This phase 2, single centre, randomised, double-blind, placebo-controlled trial included hospitalised patients between August 14, 2022, and September 26, 2022, in Sanya Central Hospital (The Third People’s Hospital of Hainan Province) in China with no severe symptoms if they had laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection for not more than 120 h (5 days) and a real-time quantitative polymerase chain reaction (qPCR) cycle threshold (Ct) value of ≤30 for both the open reading frames 1 ab (ORF1ab) and nucleocapsid (N) genes within 72 h before randomisation. Half of the participants (n = 30) were randomly assigned (2:1) to receive either RAY1216 or a matched placebo three times a day (TID) for 5 days (15 doses in total), while the other half received RAY1216 plus ritonavir (RAY1216 plus RTV) or a matched placebo every 12 h for 5 days (10 doses in total). The primary endpoint was the time of viral clearance. Secondary outcomes included the changes of the SARS-CoV-2 RNA viral load, the positivity rate of the nucleic acid test, and the recovery time of clinical symptoms. A safety evaluation was performed to record and analyse all adverse events that occurred during and after drug administration as well as any cases in which dosing was halted because of these events. Clinicaltrials.gov identifier: ChiCTR2200062889. The viral shedding times in the RAY1216 and RAY1216 plus RTV groups were 166 h (95% confidence interval (CI): 140–252) and 155 h (95%CI: 131–203), respectively, which were 100 h (4.2 days) and 112 h (4.6 days) shorter than that of the placebo group, respectively (RAY1216 group vs. Placebo p = 0.0060, RAY1216 plus RTV group vs. Placebo p = 0.0001). At 24 h, 72 h, and 120 h after administration, the viral RNA loads in the RAY1216 and RAY1216 plus RTV groups were significantly less than those of the placebo groups. At 280 h (11.5 days) after administration, the nucleic acid test results in the RAY1216 and RAY1216 plus RTV groups were both negative. The common adverse events related to the investigational drugs were mild and self-limiting laboratory examination abnormalities. Our findings suggest that RAY1216 monotherapy and RAY1216 plus ritonavir both demonstrated significant antiviral activity and reduced the duration of COVID-19 while maintaining a satisfactory safety profile. Considering the limited clinical application of RTV, it is recommended to use RAY1216 alone to further verify its efficacy and safety. This study was sponsored by the Key Research and Development Program of China (2022YFC0868700).

10 April 2024 in eClinicalMedicine
Verified
Journal Article
Open access
HLHongzhou Lu
Hongzhou Lu
GZGeorge Zhang
George Zhang
JMJohn Mao
John Mao
XCXiaochun Chen
Xiaochun Chen
YZYangqing Zhan
Yangqing Zhan
NZNanshan Zhong
Nanshan Zhong
GST-HG171 is a potent, broad-spectrum, orally bioavailable small-molecule 3C like protease inhibitor that has demonstrated greater potency and efficacy compared to Nirmatrelvir in pre-clinical studies. We aimed to evaluate the efficacy and safety of orally administered GST-HG171 plus Ritonavir in patients with coronavirus disease 2019 (COVID-19) infected with emerging XBB and non-XBB variants. This randomised, double-blind, placebo-controlled phase 2/3 trial was conducted in 47 sites in China among adult patients with mild-to-moderate COVID-19 with symptoms onset ≤72 h. Eligible patients were randomised 1:1 to receive GST-HG171 (150 mg) plus Ritonavir (100 mg) or corresponding placebo tablets twice daily for 5 days, with stratification factors including the risk level of disease progression and vaccination status. The primary efficacy endpoint was time to sustained recovery of clinical symptoms within 28 days, defined as a score of 0 for 11 COVID-19-related target symptoms for 2 consecutive days, assessed in the modified intention-to-treat (mITT) population. This trial was registered at ClinicalTrials.gov (NCT05656443) and Chinese Clinical Trial Registry (ChiCTR2200067088). Between Dec 19, 2022, and May 4, 2023, 1525 patients were screened. Among 1246 patients who underwent randomisation, most completed basic (21.2%) or booster (74.9%) COVID-19 immunization, and most had a low risk of disease progression at baseline. 610 of 617 who received GST-HG171 plus Ritonavir and 603 of 610 who received placebo were included in the mITT population. Patients who received GST-HG171 plus Ritonavir showed shortened median time to sustained recovery of clinical symptoms compared to the placebo group (13.0 days [95.45% confidence interval 12.0–15.0] vs. 15.0 days [14.0–15.0], P = 0.031). Consistent results were observed in both SARS-CoV-2 XBB (45.7%, 481/1053 of mITT population) and non-XBB variants (54.3%, 572/1053 of mITT population) subgroups. Incidence of adverse events was similar in the GST-HG171 plus Ritonavir (320/617, 51.9%) and placebo group (298/610, 48.9%). The most common adverse events in both placebo and treatment groups were hypertriglyceridaemia (10.0% vs. 14.7%). No deaths occurred. Treatment with GST-HG171 plus Ritonavir has demonstrated benefits in symptom recovery and viral clearance among low-risk vaccinated adult patients with COVID-19, without apparent safety concerns. As most patients were treated within 2 days after symptom onset in our study, confirming the potential benefits of symptom recovery for patients with a longer duration between symptom onset and treatment initiation will require real-world studies. Fujian Akeylink Biotechnology Co., Ltd.


11 May 2026 in Frontiers in Nutrition
Verified
Journal Article
Open access
PDF file
PZPengyu Zhao
Pengyu Zhao
WFWenyun Fu
Wenyun Fu
LCLanxin Cui
Lanxin Cui
LLling Lin
ling Lin
Background: Metabolic syndrome (MetS) has emerged as an increasingly significant global health issue. The Dietary Approaches to Stop Hypertension (DASH) diet is recommended for managing MetS. However, existing meta-analyses often focus on individual MetS components, without providing a comprehensive evaluation of the DASH diet’s effects on the full spectrum of MetS components. Therefore, we conducted a systematic review and meta-analysis of randomized controlled trials evaluating the effects of the DASH diet on various components of MetS. Methods: We performed a comprehensive search of PubMed, Web of Science, Embase, and Cochrane Library databases, covering studies published until April 6, 2025. We included RCTs that evaluated the effects of the DASH diet on MetS components such as waist circumference (WC), blood pressure (BP), fasting blood glucose (FBG), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and Homeostasis Model Assessment-Insulin Resistance (HOMA-IR). Sensitivity analyses were conducted to assess result stability, and funnel plots were used to assess publication bias, with Egger’s test applied for significance ( p < 0.05). Additionally, we used the GRADE approach to assess the certainty of evidence. Results: A total of 14 studies involving 1,062 participants were included. The meta-analysis showed that, compared with non-DASH diets, the DASH diet significantly reduced WC (MD = −2.33 cm, 95% CI: −3.10 to −1.57), systolic BP (MD = −5.52 mmHg, 95% CI: −6.83 to −4.21), diastolic BP (MD = −3.93 mmHg, 95% CI: −4.76 to −3.10), TG (MD = −16.57 mg/dL, 95% CI: −23.53 to −9.61), HDL-C (MD = 1.44 mg/dL, 95% CI: 0.20 to 2.68), and HOMA-IR levels (MD = −0.71, 95% CI: −1.10 to −0.31). However, no significant difference was observed in FBG (MD = −0.91 mg/dL, 95% CI: −4.51 to 2.68). The GRADE approach for assessing certainty of evidence indicated that, with the exception of FBG and HDL-C where the certainty of evidence was low, the overall certainty of evidence for the remaining outcome measures was rated as moderate quality. Conclusion: The DASH diet appears to have a positive effect on components of MetS and can be considered an effective dietary intervention for MetS patients. Systematic review registration: CRD420251060235.

9 November 2019 in BMC Medical Genetics
Verified
Journal Article
Open access
PDF file
WJWeirong Jin
Weirong Jin
QZQiuwang Zhang
Qiuwang Zhang
BWBei Wang
Bei Wang
LPLili Pan
Lili Pan
HQHongyou Qin
Hongyou Qin
MKMichael J. Kutryk
Michael J. Kutryk
Background: Familial hypercholesterolemia (FH), an autosomal dominant genetic disorder, is underdiagnosed and undertreated. The majority of FH cases are caused by low density lipoprotein receptor (LDL-R) gene mutations. The C308Y mutation in LDL-R results in approximately 70% loss of LDL-R activity, leading to the elevation of low density lipoprotein-cholesterol (LDL-C) and an increased risk of premature coronary heart disease (CHD). The aim of this study was to identify FH cases by cascade screening in family members and relatives of a 37-year old male with premature CHD and hypercholesterolemia. Methods: Clinical exam, blood lipid profiling and genomic DNA sequencing of all exons of LDL-R were performed for the proband and his 14 family members and relatives. FH diagnosis was carried out using the Dutch Lipid Clinic Network (DLCN) criteria. Results: Lipid profiling showed that 9 individuals, including the proband, had hypercholesterolemia. All these 9 subjects had a G > A substitution at nucleotide 986 in exon 7 resulting in the C308Y mutation as determined by DNA sequencing, and all those carrying the mutation were diagnosed as having definite FH under the DLCN criteria. However, most (7/9) did not have suggestive clinical manifestations of CHD. Conclusions: The C308Y mutation was discovered in multiple family members and relatives for the first time in mainland China. Cascade screening is key for the confirmatory diagnosis of FH. Our hypothesis that the C308Y is a common variant in the population of Southern China origin warrants further validation by screening for the C308Y mutation in a large population.